AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases.

Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells.

IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.

Biotechnology

AbolerIS Pharma

AbolerIS Pharma's headquarters in Nantes, France

Ann Meulemans

Antoine Thomas

Benoit Moreaux

Tomas Van Dyck

Carole Guillonneau

Olivier Van de Steen

Michel Goldman

F.-Xavier Hubert

Hans-Dieter Volk

Guy Heynen

Bervin Bouani

Roland Buelow

Description

People (2)

Carole Guillonneau

Antoine Thomas

Jobs